Phase III Study Showed Rituxan in Combination with Chemotherapy Improved Progression-Free Survival in Patients with Relapsed CLL
Study is Second Positive Phase III Trial of Rituxan Plus Chemotherapy in Most Common Adult Leukemia
08-Oct-2008 -
Genentech, Inc. and Biogen Idec announced that a global Phase III study of Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival (PFS), as assessed by investigators, in patients with previously ...
Biogen Idec
chemotherapy
chronic lymphocytic leukemia
+4